RNA Therapeutics and RNA Vaccines Market by Type of Modality

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: OVERVIEW

As per Roots Analysis, the global RNA therapeutics market and RNA vaccines market is estimated to grow to USD 940 million by 2035, at a CAGR of 68% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Modality

RNA Therapeutics

RNA Vaccines

Type of Molecule

Replicating RNA

Self Amplifying RNA

Self Activating RNA

Self Amplifying mRNA

Transfer RNA

Therapeutic Areas

Infectious Diseases

Oncological Disorders

Route of Administration

Intradermal

Intramuscular

Intravenous

Key Geographical Regions

North America

Asia-Pacific

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: GROWTH AND TRENDS

Given the critical role it plays in producing proteins and regulating gene function in the human body, RNA is being investigated as a potential therapeutic modality. Researchers are realizing the vast potential associated with RNA-based drugs, given their ability to specifically target and treat diseases that earlier deemed untreatable. However, the highly unstable nature of such molecules offers significant resistance to their applicability as treatment options. In recent years, the advent of advanced technologies and platforms has escalated the interest of industry stakeholders towards enhanced and modified RNA-based therapies, that are believed to be highly stable and have an extended impact at relatively low doses. This class of modified RNA-based therapies is termed as next generation therapies, which are anticipated to evolve rapidly to become the next big therapeutic approach in the coming decade. Driven by the research and development efforts, high investment activity and increased involvement of prominent players, the RNA therapeutics and vaccines market is anticipated to witness significant growth in the foreseen future.

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY INSIGHTS

The report delves into the current state of the RNA therapeutics and RNA vaccines market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 100 next generation RNA therapeutics and vaccines are being developed to offer an advanced, low-dose form of treatment, targeting a wide range of therapeutic indications.

2. 75% of the next generation therapies are still in discovery and preclinical stages, primarily targeting infectious diseases; industry players are actively engaged in advancing their next generation drug portfolio.

3. Over 35 next generation RNA technologies are being developed / offered by companies for the research, discovery, design, development, manufacturing and delivery of novel RNA therapies and vaccines.

4. Around 55% of the technologies are used in the development of circular RNA-based therapeutics and vaccines; majority of such technologies facilitate targeted therapy delivery at a specific site within the cell.

5. Majority of the trials focused on RNA therapeutics and vaccines were registered in 2022; more than 70% of these studies have either been completed / are currently recruiting patients across different locations.

6. Close to 1,170 patents have been filed / granted for next generation RNA therapeutics and vaccines, by industry and non-industry players, to protect intellectual property generated within this field.

7. Around 70% of the deals inked in this market were focused on clinical research of saRNA therapeutics / vaccines; of these, more than 60% partnerships were inked for the treatment of infectious diseases.

8. Several investors, having realized the opportunity within this domain, have invested close to USD 2.9 Billion across various funding rounds in the past four years.

9. The rising interest of big pharma players is reflected by the increase in the number of next generation RNA therapeutics / vaccines-focused initiatives, including partnerships and funding, undertaken in recent years.

10. The market opportunity associated with next generation RNA therapeutics and vaccines is expected to witness an annualized growth rate of more than 50% between 2026 to 2035.

RNA THERAPEUTICS MARKET AND RNA VACCINES MARKET: KEY SEGMENTS

Vaccines Account for the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the type of modality, the market is segmented into RNA therapeutics and RNA vaccines. At present, RNA vaccines capture a substantial proportion of the RNA therapeutics and RNA vaccines market. This trend is unlikely to change in the near future.

repRNA Dominates the RNA Therapeutics and RNA Vaccines Market During the Forecast Period

Based on the type of molecule, the market is segmented into replicating RNA, self amplifying RNA, self activating RNA, self amplifying mRNA and transfer RNA. At present, replicating RNA holds the maximum share of the the RNA therapeutics and RNA vaccines market. However, self amplifying RNA is likely to drive the market in the near future.

Infectious Diseases Segment Captures the Highest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the therapeutic area, the market is segmented into infectious diseases and oncological disorders. Currently, infectious diseases account for the 100% share of the RNA therapeutics and RNA vaccines market. However, oncological disorders segment is likely to drive the market in the near future.

Intradermal Route Occupies for the Largest Share of the RNA Therapeutics and RNA Vaccines Market

Based on the route of administration, the market is segmented into intradermal, intramuscular and intravenous. Currently, the intradermal route holds the majority share of the RNA therapeutics and RNA vaccines market. However, the intramuscular route is likely to drive the market in the near future.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America and Asia-Pacific. The majority of the share is expected to be captured by drug developers based in Asia-Pacific. It is worth highlighting that, over the years, the market in North America is expected to grow at a higher CAGR.

Example Players in the RNA Therapeutics and RNA Vaccines Market

Alphavax

Arcturus Therapeutics

Atyr Pharma

Gritstone Bio

HDT Bio

MiNA Therapeutics

VLP Therapeutics

RNA THERAPEUTICS AND RNA VACCINES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the RNA therapeutics and RNA vaccines market, focusing on key market segments, including [A] type of modality, [B] type of molecule, [C] therapeutic areas, [D] route of administration [E] and [F] key geographical regions.

Market Landscape: A comprehensive evaluation of next generation RNA therapeutics and RNA vaccines that are either approved or being evaluated in different stages of development, considering various parameters, such as [A] type of modality, [B] type of molecule, [C] type of delivery vehicle, [D] phase of development [E] therapeutic area and [F] key niche market segments (circRNA and saRNA). Additionally, the chapter includes analysis of various next generation RNA therapeutic and RNA vaccine developers, based on their [G] year of establishment, [H] company size, [I] location of headquarters and [J] most active players (in terms of number of therapies).

Technology Landscape: A comprehensive evaluation of technologies that are being developed / deployed to support the development of next generation RNA therapeutics and RNA vaccines, considering various parameters, such as [A] class of molecule, [B] type of molecule, [C] capabilities of the technology, [D] therapeutic area and [E] highest phase of development. Additionally, the chapter features analysis of various next generation RNA therapeutic and RNA vaccine technology developers, based on their [F] year of establishment, [G] company size, [H] location of headquarters and [I] operational model.

Drug Profiles: In-depth profiles of drug candidates that are in advanced stages of development, focusing on [A] details on its developer, [B] drug overview, [C] clinical trial information, [D] clinical trial endpoints, [E] clinical trial results and [F] estimated sales.

Clinical Trial Analysis: Examination of completed, ongoing, and planned clinical studies of various next generation RNA therapeutics and RNA vaccines, based on parameters like [A] trial registration year, [B] trial status, [C] trial phase, [D] patients enrolled, [E] type of sponsor, [F] therapeutic area, [G] study design, [H] leading organizations (in terms of number of trials), [I] focus area and [J] geography.

Patent Analysis: Detailed analysis of various patents filed / granted related to next generation RNA therapeutics and RNA vaccines based on [A] type of patent (granted patents, patent applications and others), [B] patent publication year, [C] patent jurisdiction, [D] CPC symbols, [E] emerging focus areas, [F] patent age, [G] leading industry / non-industry players (in terms of number of patents filed / granted) and [H] patent valuation.

Partnerships and Collaborations: An analysis of partnerships established in this sector based on several relevant parameters, such as the [A] year of partnership, [B] type of partnership, [C] type of molecule, [D] focus of partnership, [E] purpose of partnership, [F] therapeutic area, [G] most active players (in terms of number of partnerships) and [H] the regional distribution of partnership activity in this market.

Funding and Investment Analysis: A detailed evaluation of the investments made in this domain based on several relevant parameters, such as [A] year of funding, [B] type of funding, [C] type of molecule, [D] amount invested, [E] geography, [F] purpose of funding, [G] stage of development, [H] therapeutic area, [I] most active players (in terms of number and amount of funding instances) and [J] leading investors (in terms of number of funding instances).

Big Pharma Analysis: A comprehensive examination of various initiatives focused on next generation RNA therapeutics and RNA vaccines undertaken by major pharmaceutical companies based on several relevant parameters, such as [A] number of initiatives, [B] year of initiative, [C] type of initiative, [D] purpose of initiative, [E] focus of initiative and [F] location of headquarters.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?

Which are the leading companies in this market?

What kind of partnership models are commonly adopted by industry stakeholders?

What factors are likely to influence the evolution of this market?

What is the current and future market size?

What is the CAGR of this market?

How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.

Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.

The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs

Complimentary Excel Data Packs for all Analytical Modules in the Report

Free Updated report if the report is 6-12 months old or older